SurModics/$SRDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About SurModics
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
Ticker
$SRDX
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
389
ISIN
US8688731004
Website
SurModics Metrics
BasicAdvanced
$416M
-
-$1.40
1.30
-
Price and volume
Market cap
$416M
Beta
1.3
52-week high
$42.44
52-week low
$26.00
Average daily volume
69K
Financial strength
Current ratio
5.143
Quick ratio
3.766
Long term debt to equity
26.874
Total debt to equity
26.874
Interest coverage (TTM)
-1.14%
Profitability
EBITDA (TTM)
4.514
Gross margin (TTM)
74.67%
Net profit margin (TTM)
-16.34%
Operating margin (TTM)
-3.27%
Effective tax rate (TTM)
-36.29%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-1.44%
Return on equity (TTM)
-16.96%
Valuation
Price to revenue (TTM)
3.402
Price to book
3.77
Price to tangible book (TTM)
9.14
Price to free cash flow (TTM)
-55.573
Free cash flow yield (TTM)
-1.80%
Free cash flow per share (TTM)
-52.35%
Growth
Revenue change (TTM)
-14.96%
Earnings per share change (TTM)
-246.55%
3-year revenue growth (CAGR)
7.84%
10-year revenue growth (CAGR)
7.58%
3-year earnings per share growth (CAGR)
22.50%
10-year earnings per share growth (CAGR)
4.21%
What the Analysts think about SurModics
Analyst ratings (Buy, Hold, Sell) for SurModics stock.
Bulls say / Bears say
Surmodics secured a group purchasing agreement with Premier, Inc., granting access to over 4,350 U.S. hospitals and 300,000 other providers, potentially expanding its market reach for thrombectomy products. (stocktitan.net)
The company reported a 10% year-over-year increase in Medical Device revenue (excluding the SurVeil DCB license fee) in Q3 FY2024, indicating strong organic growth in its core segment. (stocktitan.net)
Surmodics announced the commercial release of the Pounce™ XL Thrombectomy System, designed for rapid non-surgical clot removal in iliac and femoral arteries, showcasing its commitment to innovative product development. (stocktitan.net)
The U.S. Federal Trade Commission sued to block Surmodics' acquisition by private equity firm GTCR, citing concerns over reduced competition and potential increases in healthcare costs. (reuters.com)
In Q2 FY2025, Surmodics reported a 12.1% year-over-year decline in total revenues, missing consensus estimates by 8.7%, raising concerns about its financial performance. (finviz.com)
Analysts have initiated coverage on Surmodics with a 'hold' rating, reflecting cautious sentiment and potential uncertainty about the company's future growth prospects. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
SurModics Financial Performance
Revenues and expenses
SurModics Earnings Performance
Company profitability
SurModics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for SurModics stock?
SurModics (SRDX) has a market cap of $416M as of June 28, 2025.
What is the P/E ratio for SurModics stock?
The price to earnings (P/E) ratio for SurModics (SRDX) stock is 0 as of June 28, 2025.
Does SurModics stock pay dividends?
No, SurModics (SRDX) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next SurModics dividend payment date?
SurModics (SRDX) stock does not pay dividends to its shareholders.
What is the beta indicator for SurModics?
SurModics (SRDX) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.